Status: Recruiting
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndrome.
Participants needed: 304
Trial details
Phase: Phase 1, Phase 2Age: 35-85Biological sex: AllType: InterventionalSponsor: AC Immune SAUpdated: May 29, 2026Locations: 26
Eligibility criteria
Age ≥50 and ≤85 years at screening. [+9]
Any unstable and/or clinically significant medical condition likely to hamper th... [+31]